ReNerve has listed on the ASX with a ticker code of RNV. The company is focussed on the development of bio-material based medical devices that deliver superior outcomes in the treatment of peripheral nerve injury and related applications. ReNerve’s first product, the NervAlign® Nerve Cuff, has received regulatory clearance from the FDA and launched in the US.
Website: https://renerve.com.au/
Board: Dr Julian Chick – Director, Dr David Rhodes – Director & CSO, Mr Reginald Stephen Cooper – Independent Chairman, Dr Michael Panaccio – Independent Non-executive Director, Dr Alex Adamides MD FRACS – Chief Medical Officer (CMO)
Media: The Stock Network Lel Smits